CL2007003583A1 - Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. - Google Patents
Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- CL2007003583A1 CL2007003583A1 CL200703583A CL2007003583A CL2007003583A1 CL 2007003583 A1 CL2007003583 A1 CL 2007003583A1 CL 200703583 A CL200703583 A CL 200703583A CL 2007003583 A CL2007003583 A CL 2007003583A CL 2007003583 A1 CL2007003583 A1 CL 2007003583A1
- Authority
- CL
- Chile
- Prior art keywords
- formulation
- abeta
- alzheimer
- disease
- stable
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06025590 | 2006-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003583A1 true CL2007003583A1 (es) | 2008-07-18 |
Family
ID=39190366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703583A CL2007003583A1 (es) | 2006-12-11 | 2007-12-11 | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110070225A1 (enExample) |
| EP (1) | EP2094729A1 (enExample) |
| JP (1) | JP2010512356A (enExample) |
| KR (1) | KR20090104017A (enExample) |
| CN (1) | CN101553504A (enExample) |
| AR (1) | AR064220A1 (enExample) |
| AU (1) | AU2007331712A1 (enExample) |
| BR (1) | BRPI0721097A2 (enExample) |
| CA (1) | CA2671968A1 (enExample) |
| CL (1) | CL2007003583A1 (enExample) |
| CR (1) | CR10823A (enExample) |
| EC (1) | ECSP099403A (enExample) |
| IL (1) | IL198963A0 (enExample) |
| MA (1) | MA30975B1 (enExample) |
| MX (1) | MX2009006199A (enExample) |
| NO (1) | NO20092586L (enExample) |
| PE (1) | PE20081477A1 (enExample) |
| RU (1) | RU2009126420A (enExample) |
| TW (1) | TW200831133A (enExample) |
| WO (1) | WO2008071394A1 (enExample) |
| ZA (1) | ZA200904014B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| WO2006106903A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
| US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| UY30003A1 (es) * | 2005-12-12 | 2007-08-31 | Hoffmann La Roche | Anticuerpos glicosilados en la region variable |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PT2238166E (pt) | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
| AU2008352540B2 (en) | 2008-03-14 | 2012-06-28 | Biocon Limited | A monoclonal antibody and a method thereof |
| JP6146949B2 (ja) * | 2008-06-20 | 2017-06-21 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
| KR20140019035A (ko) * | 2008-09-19 | 2014-02-13 | 에프. 호프만-라 로슈 아게 | 신규한 항체 제형 |
| KR101593285B1 (ko) * | 2008-10-29 | 2016-02-11 | 아블린쓰 엔.브이. | 단일 도메인 항원 결합 분자의 제형 |
| MX2011004558A (es) | 2008-10-29 | 2011-06-01 | Wyeth Llc | Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio. |
| AR074357A1 (es) * | 2008-11-17 | 2011-01-12 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| WO2010100179A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| KR101333276B1 (ko) * | 2009-11-20 | 2013-11-27 | 센트로 데 인무노로지아 몰레큘라 | 항체의 제제 |
| BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| PH12012501742A1 (en) | 2010-03-01 | 2022-03-21 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| BR112012022102A2 (pt) | 2010-03-03 | 2017-01-10 | Boehringer Ingelheim Int | polipeptídeos de ligação a a-beta. |
| CN102933601B (zh) | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| MX2012013586A (es) | 2010-05-28 | 2013-01-24 | Novo Nordisk As | Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante. |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| WO2012028683A1 (en) * | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| ES2646717T3 (es) | 2011-05-02 | 2017-12-15 | Millennium Pharmaceuticals, Inc. | Formulación para anticuerpo anti- 4 7 |
| EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| JP6431372B2 (ja) | 2011-10-25 | 2018-11-28 | プロシーナ バイオサイエンシーズ リミテッド | 抗体製剤および方法 |
| DK2822587T3 (en) * | 2012-03-08 | 2016-02-29 | Hoffmann La Roche | ABETA ANTIBODY FORMULATION |
| PL2830658T3 (pl) * | 2012-03-26 | 2019-02-28 | Sanofi | Stabilne formulacje środków wiążących lgG4 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US20160002342A1 (en) * | 2013-03-15 | 2016-01-07 | Xinghang Ma | Anti-prolactin receptor antibody formulations |
| PT3024485T (pt) | 2013-07-23 | 2021-01-25 | Biocon Ltd | Utilização de um parceiro de ligação de cd6 e método baseado no mesmo |
| EP3825324A1 (en) | 2014-10-24 | 2021-05-26 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| EP3207936B1 (en) * | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN104946616A (zh) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | 一种用于体外诊断试剂的通用固体稳定剂及其使用方法 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| WO2016207240A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| HUE061985T2 (hu) * | 2015-08-19 | 2023-09-28 | Astrazeneca Ab | Stabil IFNAR1-elleni készítmény |
| KR20180037056A (ko) * | 2015-09-22 | 2018-04-10 | 화이자 인코포레이티드 | 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형 |
| CN114057884A (zh) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CN106620691B (zh) * | 2015-11-04 | 2020-08-21 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
| SG11201804961UA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
| CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
| ES2991182T3 (es) | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
| CN106913869B (zh) * | 2017-03-17 | 2020-07-28 | 信达生物制药(苏州)有限公司 | 一种抗ctla-4单克隆抗体制剂及其应用 |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| AU2018321335B2 (en) * | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CN108373494A (zh) * | 2018-02-27 | 2018-08-07 | 武汉伊艾博科技有限公司 | 一种防止重组蛋白质降解的保护技术 |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| WO2022072255A1 (en) * | 2020-09-30 | 2022-04-07 | Merck Sharp & Dohme Corp. | Binding proteins and antigen binding fragments thereof that bind abeta |
| WO2024246085A1 (en) | 2023-05-31 | 2024-12-05 | F. Hoffmann-La Roche Ag | Therapeutic use of bispecific anti-abeta/tfr antibodies |
| CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| ES2338218T3 (es) * | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| JP4869064B2 (ja) * | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| KR20070107079A (ko) * | 2005-01-28 | 2007-11-06 | 와이어쓰 | 안정화된 액체 폴리펩타이드 제형 |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| UY30003A1 (es) * | 2005-12-12 | 2007-08-31 | Hoffmann La Roche | Anticuerpos glicosilados en la region variable |
| CN101410137A (zh) * | 2006-03-28 | 2009-04-15 | 霍夫曼-拉罗奇有限公司 | 抗-igf-1r人单克隆抗体制剂 |
-
2007
- 2007-12-11 MX MX2009006199A patent/MX2009006199A/es not_active Application Discontinuation
- 2007-12-11 CL CL200703583A patent/CL2007003583A1/es unknown
- 2007-12-11 KR KR1020097013954A patent/KR20090104017A/ko not_active Withdrawn
- 2007-12-11 AU AU2007331712A patent/AU2007331712A1/en not_active Abandoned
- 2007-12-11 PE PE2007001764A patent/PE20081477A1/es not_active Application Discontinuation
- 2007-12-11 WO PCT/EP2007/010825 patent/WO2008071394A1/en not_active Ceased
- 2007-12-11 EP EP07856573A patent/EP2094729A1/en not_active Withdrawn
- 2007-12-11 AR ARP070105523A patent/AR064220A1/es unknown
- 2007-12-11 TW TW096147285A patent/TW200831133A/zh unknown
- 2007-12-11 US US12/448,190 patent/US20110070225A1/en not_active Abandoned
- 2007-12-11 JP JP2009540650A patent/JP2010512356A/ja not_active Withdrawn
- 2007-12-11 CA CA002671968A patent/CA2671968A1/en not_active Abandoned
- 2007-12-11 RU RU2009126420/10A patent/RU2009126420A/ru not_active Application Discontinuation
- 2007-12-11 CN CNA2007800455861A patent/CN101553504A/zh active Pending
- 2007-12-11 BR BRPI0721097-3A patent/BRPI0721097A2/pt not_active IP Right Cessation
-
2009
- 2009-05-21 CR CR10823A patent/CR10823A/es not_active Application Discontinuation
- 2009-05-26 IL IL198963A patent/IL198963A0/en unknown
- 2009-06-08 MA MA31963A patent/MA30975B1/fr unknown
- 2009-06-09 ZA ZA200904014A patent/ZA200904014B/xx unknown
- 2009-06-11 EC EC2009009403A patent/ECSP099403A/es unknown
- 2009-07-07 NO NO20092586A patent/NO20092586L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20092586L (no) | 2009-07-17 |
| US20110070225A1 (en) | 2011-03-24 |
| WO2008071394A1 (en) | 2008-06-19 |
| PE20081477A1 (es) | 2008-10-18 |
| JP2010512356A (ja) | 2010-04-22 |
| CA2671968A1 (en) | 2008-06-19 |
| IL198963A0 (en) | 2011-08-01 |
| AU2007331712A2 (en) | 2009-07-30 |
| AU2007331712A1 (en) | 2008-06-19 |
| EP2094729A1 (en) | 2009-09-02 |
| KR20090104017A (ko) | 2009-10-05 |
| TW200831133A (en) | 2008-08-01 |
| BRPI0721097A2 (pt) | 2014-07-01 |
| MA30975B1 (fr) | 2009-12-01 |
| AR064220A1 (es) | 2009-03-18 |
| CN101553504A (zh) | 2009-10-07 |
| RU2009126420A (ru) | 2011-01-20 |
| MX2009006199A (es) | 2009-06-22 |
| ZA200904014B (en) | 2010-04-28 |
| CR10823A (es) | 2009-08-12 |
| ECSP099403A (es) | 2009-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003583A1 (es) | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. | |
| CL2004001011A1 (es) | Compuestos azabiciclicos derivados de n-arilsulfonilpiperidinas; inhibidores de la deposicion de la proteina beta amiloide; composicion farmaceutica; y su uso para el tratamiento del alzheimer y enfermedades neurodegenerativas. | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2007003192A1 (es) | Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario. | |
| CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
| DOP2006000099A (es) | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos | |
| CL2007003797A1 (es) | Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades. | |
| BRPI0816255A2 (pt) | Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| BRPI0811267A2 (pt) | Variante de fenilanina amônia-liase procariótica, composição farmacêutica, método para o tratamento de uma doença, uso de uma variante de fenilalanina amônia-liase procariótica, método para o tratamento de uma condição, e, variante de fenilalanina amônia-liase de anabaena variabilis. | |
| CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| BRPI1012993A2 (pt) | "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro" | |
| CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| CL2007000806A1 (es) | Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| WO2007022380A3 (en) | Bis-aryl amide compounds and methods of use | |
| CL2011001098A1 (es) | Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras. | |
| CL2007002897A1 (es) | Uso de un antagonista (sartan) del receptor 1 (at-1) de angiotensina ii para la preparacion de una composicion farmaceutica para el tratamiento de una enfermedad generalizada en gatos; metodo para la profilaxis o el tratamiento de una enfermedad en g | |
| AR069135A1 (es) | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide | |
| BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
| CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. |